All In Biotech

Drug Trial Radar · NCT03523858

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

927

Actual

Start

May 28, 2018

Primary completion

Oct 22, 2026

Study completion Oct 22, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Conditions

  • Progressive Multiple Sclerosis (PMS)

Interventions

  • OcrelizumabDrug

    Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with No Evidence of Progression (NEP)Time frame: From Baseline to Week 96, Week 96 to Week 192 and Baseline to Week 192
  2. Proportion of Participants with no evidence of progression and no active disease (NEPAD)Time frame: From Baseline to Week 96, Week 96 to Week 192 and Baseline to Week 192

Locations

120 sites in 24 countries. Site status is shown where the registry gives one.

  • MS Center of California

    Laguna Hills, California

  • SC3 Research Group, Inc

    Pasadena, California

  • University of California San Francisco

    San Francisco, California

  • University of South Florida

    Tampa, Florida

  • University of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dragonfly Research, LLC

    Wellesley, Massachusetts

  • Wayne State University School of Medicine

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • The MS Center of Northeastern New York

    Latham, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • Neurology Clinic PC

    Cordova, Tennessee

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • Lone Star Neurology of San Antonio

    San Antonio, Texas

  • Swedish Multiple Sclerosis Center

    Seattle, Washington

  • University Clinical Center of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • University Hospital Mostar

    Mostar, Bosnia and Herzegovina

  • Clinical Center University of Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • University Clinical Center Tuzla

    Tuzla, Bosnia and Herzegovina

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto

    Ribeirão Preto, São Paulo, Brazil

  • Hospital das Clinicas - FMUSP_X

    São Paulo, São Paulo, Brazil

  • Fraser Health Authority - Fraser Health Multiple Sclerosis

    Burnaby, British Columbia, Canada

  • University of British Columbia Hospital

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre Uni Campus

    London, Ontario, Canada

  • St. Michael'S Hospital

    Toronto, Ontario, Canada

  • Recherche Sepmus Inc.

    Greenfield Park, Quebec, Canada

  • Hospital Notre-Dame du Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada

  • Saskatoon City Hospital

    Saskatoon, Saskatchewan, Canada

  • Organizacion Sanitas Internacional

    Bogotá, Colombia

  • Fundacion Clinica Valle del Lili

    Cali, Colombia

  • Hospital Clínica Biblica

    San José, Costa Rica

  • Nemocnice Jihlava

    Jihlava, Czechia

  • Fakultní Nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava-Poruba, Czechia

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Aarhus Universitetshospital

    Aarhus N, Denmark

  • Rigshospitalet

    Glostrup Municipality, Denmark

  • Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken

    Sønderborg, Denmark

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.